Who Paid My Doc
Daniel Brubaker
Immunopathology Fresno, CA Doctor of Osteopathy
NPI 1467559526 CMS profile 1088031
3726 N 1St St, Fresno, CA 93726
General payments
$147
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Daniel Brubaker of Fresno, CA is reported in the CMS Open Payments database as having received $147 across 10 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $15 | 1 | |
| 2021 | General | $15 | 1 | |
| 2020 | General | $11 | 1 | |
| 2019 | General | $107 | 7 |
Beside peers
- Daniel Brubaker
- California median
- Middle half of California
- National median
In program year 2025, general payments to Daniel Brubaker were reported at $0. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Daniel Brubaker | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $107 | $161 | $50–$652 | $163 |
| 2020 | $11 | $114 | $34–$392 | $114 |
| 2021 | $15 | $137 | $41–$509 | $132 |
| 2022 | $15 | $152 | $48–$573 | $149 |
| 2023 | $0 | $162 | $50–$581 | $160 |
| 2024 | $0 | $162 | $52–$583 | $164 |
| 2025 | $0 | $172 | $54–$610 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 19 drugsPart D claims
374
Drug cost
$3,417
Branded share of claims
8.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Memantine Hcl | Generic | 35 | $674 | |
| Celecoxib | Generic | 15 | $506 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 22 | $382 | |
| Bupropion Hcl | Generic | 13 | $257 | |
| Nortriptyline Hcl | Generic | 32 | $231 | |
| Amitriptyline Hcl | Generic | 15 | $215 | |
| Tramadol Hcl | Generic | 38 | $206 | |
| Omeprazole | Generic | 28 | $204 | |
| Ibuprofen | Generic | 19 | $130 | |
| Gabapentin | Generic | 16 | $124 |
The 10 drugs with the highest cost, of 19 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$11,591
Medicare patients
23
Services billed
130
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 61% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Immunopathology in California
Related records
Immunopathology in California
Practitioners in the same specialty and state, ranked by reported value.
All Immunopathology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.